Zohreh Amoozgar

Zohreh Amoozgar

Publications

Hide
Gomes-Santos IL, Kumar AS, Hausmann F, Meyer MN, Shiferaw SZ, Amoozgar Z, Jain RK, Fukumura D
Exercise intensity governs tumor control in mice with breast cancer.
Front Immunol. 2024;15:1339232 - PMID: 38495879 - PMCID: PMC10940460 - DOI: 10.3389/fimmu.2024.1339232
Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin SM, Matsui A, Hernandez A, Pu Z, Halvorsen S, Lei PJ, Datta M, Zhu L, Ruan Z, Shi L, Staiculescu D, Inoue K, Munn LL, Fukumura D, Huang P, Sassi S, Bardeesy N, Ho WJ, Jain RK, Duda DG
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Cancer Immunol Res. 2024;12(4):400-412 - PMID: 38260999 - PMCID: PMC10985468 - DOI: 10.1158/2326-6066.CIR-23-0486
Jain R, Krishnan S, Lee S, Amoozgar Z, Subudhi S, Kumar A, Posada J, Lindeman N, Lei P, Duquette M, Roberge S, Huang P, Andersson P, Datta M, Munn L, Fukumura D
Wnt inhibition alleviates resistance to immune checkpoint blockade in glioblastoma.
Res Sq. 2023;:ePub - PMID: 38234841 - PMCID: PMC10793505 - DOI: 10.21203/rs.3.rs-3707472/v1
Lei PJ, Pereira ER, Andersson P, Amoozgar Z, Van Wijnbergen JW, O'Melia MJ, Zhou H, Chatterjee S, Ho WW, Posada JM, Kumar AS, Morita S, Menzel L, Chung C, Ergin I, Jones D, Huang P, Beyaz S, Padera TP
Cancer cell plasticity and MHC-II-mediated immune tolerance promote breast cancer metastasis to lymph nodes.
J Exp Med. 2023;220(9):ePub - PMID: 37341991 - PMCID: PMC10286805 - DOI: 10.1084/jem.20221847
Dong X, Ren J, Amoozgar Z, Lee S, Datta M, Roberge S, Duquette M, Fukumura D, Jain RK
Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
J Immunother Cancer. 2023;11(3):ePub - PMID: 36898734 - PMCID: PMC10008211 - DOI: 10.1136/jitc-2022-005583
Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin S, Matsui A, Pu Z, Lei PJ, Datta M, Zhu L, Ruan Z, Shi L, Staiculescu D, Inoue K, Munn LL, Fukumura D, Huang P, Bardeesy N, Ho WJ, Jain RK, Duda DG
Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
bioRxiv. 2023;:ePub - PMID: 36747853 - PMCID: PMC9901023 - DOI: 10.1101/2023.01.26.525680
Kikuchi H, Matsui A, Morita S, Amoozgar Z, Inoue K, Ruan Z, Staiculescu D, Wong JS, Huang P, Yau T, Jain RK, Duda DG
Increased CD8+ T-Cell Infiltration and Efficacy for Multikinase Inhibitors after PD-1 Blockade in Hepatocellular Carcinoma.
J Natl Cancer Inst. 2022;114(9):1301-1305 - PMID: 35288743 - PMCID: PMC9468280 - DOI: 10.1093/jnci/djac051
Xiao Y, Chen J, Zhou H, Zeng X, Ruan Z, Pu Z, Jiang X, Matsui A, Zhu L, Amoozgar Z, Chen DS, Han X, Duda DG, Shi J
Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy.
Nat Commun. 2022;13(1):758 - PMID: 35140208 - PMCID: PMC8828745 - DOI: 10.1038/s41467-022-28279-8
Ho WW, Gomes-Santos IL, Aoki S, Datta M, Kawaguchi K, Talele NP, Roberge S, Ren J, Liu H, Chen IX, Andersson P, Chatterjee S, Kumar AS, Amoozgar Z, Zhang Q, Huang P, Ng MR, Chauhan VP, Xu L, Duda DG, Clark JW, Pittet MJ, Fukumura D, Jain RK
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
Proc Natl Acad Sci U S A. 2021;118(45):ePub - PMID: 34725151 - PMCID: PMC8609309 - DOI: 10.1073/pnas.2105323118
Amoozgar Z, Kloepper J, Ren J, Tay RE, Kazer SW, Kiner E, Krishnan S, Posada JM, Ghosh M, Mamessier E, Wong C, Ferraro GB, Batista A, Wang N, Badeaux M, Roberge S, Xu L, Huang P, Shalek AK, Fukumura D, Kim HJ, Jain RK
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
Nat Commun. 2021;12(1):2582 - PMID: 33976133 - PMCID: PMC8113440 - DOI: 10.1038/s41467-021-22885-8
Gomes-Santos IL, Amoozgar Z, Kumar AS, Ho WW, Roh K, Talele NP, Curtis H, Kawaguchi K, Jain RK, Fukumura D
Exercise training improves tumor control by increasing CD8+ T-cell infiltration via CXCR3 signaling and sensitizes breast cancer to immune checkpoint blockade.
Cancer Immunol Res. 2021;9(7):765-778 - PMID: 33839688 - PMCID: PMC8295193 - DOI: 10.1158/2326-6066.CIR-20-0499
Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, Possada JM, Chen J, Chin CR, Amoozgar Z, Ferreira R, Chen IX, Naxerova K, Ng C, Westermark AM, Duquette M, Roberge S, Lindeman NI, Lyssiotis CA, Nielsen J, Housman DE, Duda DG, Brachtel E, Golub TR, Cantley LC, Asara JM, Davidson SM, Fukumura D, Dartois VA, Clish CB, Jain, RK, Vander Heiden MG
Fatty acid synthesis is required for breast cancer brain metastasis
Nature Cancer. 2021;:ePub
Krishnan S, Amoozgar Z, Fukumura D, Jain RK
Implications of a granulocyte-high glioblastoma microenvironment in immune suppression and therapy resistance†.
J Pathol. 2021;254(2):105-108 - PMID: 33534142 - PMCID: PMC8262382 - DOI: 10.1002/path.5637
Amoozgar Z, Jain RK, Duda DG
Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System?
Cancer Res. 2019;79(9):2104-2106 - PMID: 31043429 - PMCID: PMC6601607 - DOI: 10.1158/0008-5472.CAN-19-0749
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Nat Rev Clin Oncol. 2018;15(5):325-340 - PMID: 29508855 - PMCID: PMC5921900 - DOI: 10.1038/nrclinonc.2018.29
Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, Kurtulus S, Kassam N, Sobel RA, Fukumura D, Jain RK, Anderson AC, Kuchroo VK, Joller N
Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity.
J Immunol. 2018;200(8):3000-3007 - PMID: 29500245 - PMCID: PMC5893394 - DOI: 10.4049/jimmunol.1700407
Askoxylakis V, Badeaux M, Roberge S, Batista A, Kirkpatrick N, Snuderl M, Amoozgar Z, Seano G, Ferraro GB, Chatterjee S, Xu L, Fukumura D, Duda DG, Jain RK
A cerebellar window for intravital imaging of normal and disease states in mice.
Nat Protoc. 2017;12(11):2251-2262 - PMID: 28981123 - PMCID: PMC5918134 - DOI: 10.1038/nprot.2017.101
Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Proc Natl Acad Sci U S A. 2016;113(16):4470-5 - PMID: 27044097 - PMCID: PMC4843449 - DOI: 10.1073/pnas.1525349113
Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Proc Natl Acad Sci U S A. 2016;113(16):4476-81 - PMID: 27044098 - PMCID: PMC4843473 - DOI: 10.1073/pnas.1525360113